GlassScriptPhysician profile
Xiuqing Ru
NPI 1679508790
$27,955.78
in general payments reported to CMS, 2019-2025
65 companies · $659 in 2025
The $659 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,730 · 2020: $2,155 · 2021: $5,087 · 2022: $8,884 · 2023: $5,068 · 2024: $372 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916 · Consulting Fee: $2,818 · Travel and Lodging: $350 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,916.26 |
| Consulting Fee | $2,818.00 |
| Travel and Lodging | $350.10 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,952.98 | 2019-2023 | Calquence |
| Incyte Corporation | $3,550.84 | 2019-2023 | Jakafi, Monjuvi |
| Kite Pharma, INC. | $3,396.38 | 2020-2022 | |
| Genzyme Corporation | $2,288.78 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $1,762.31 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,534.03 | 2019-2023 | Pomalyst, Opdivo, Eliquis |
| Celgene Corporation | $1,011.88 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $906.42 | 2019-2025 | |
| Amgen INC. | $793.97 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Pfizer INC. | $640.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $639.94 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $612.25 | 2020-2023 | Tukysa, Adcetris |
| Astellas Pharma US INC | $591.14 | 2019-2025 | Xtandi, Xospata |
| Bayer Healthcare Pharmaceuticals INC. | $563.33 | 2019-2023 | |
| Eisai INC. | $508.34 | 2019-2024 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiuqing Ru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.